170 related articles for article (PubMed ID: 15288829)
1. Radioimmunodetection and radioimmunotherapy of head and neck cancer.
Börjesson PK; Postema EJ; de Bree R; Roos JC; Leemans CR; Kairemo KJ; van Dongen GA
Oral Oncol; 2004 Sep; 40(8):761-72. PubMed ID: 15288829
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunodetection of head and neck cancer. A review.
Hopsu EV; Kairemo KJ
Acta Oncol; 1993; 32(7-8):735-40. PubMed ID: 8305220
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
[TBL] [Abstract][Full Text] [Related]
4. [Monoclonal antibodies. An approach to diagnosis and treatment of micrometastases].
Bier H
HNO; 1994 May; 42(5):255-6. PubMed ID: 8050912
[No Abstract] [Full Text] [Related]
5. Current perspectives in the use of monoclonal antibodies for detection and treatment of head and neck tumors.
Quak J; van Dongen G
Eur Arch Otorhinolaryngol; 1994; 251(1):1-5. PubMed ID: 8179860
[TBL] [Abstract][Full Text] [Related]
6. The feasibility of radioimmunotherapy of head and neck cancer.
Gerretsen M; Quak JJ; Brakenhoff RH; Snow GB; van Dongen GA
Eur J Cancer B Oral Oncol; 1994; 30B(2):82-7. PubMed ID: 8032305
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab')2 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Wilhelm AJ; van Lingen A; Snow GB; Dongen GA
Clin Cancer Res; 1995 Mar; 1(3):277-86. PubMed ID: 9815983
[TBL] [Abstract][Full Text] [Related]
8. Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer.
van Dongen GA; Brakenhoff RM; ten Brink CT; van Gog FB; de Bree R; Quak JJ; Snow GB
Anticancer Res; 1996; 16(4C):2409-13. PubMed ID: 8816843
[TBL] [Abstract][Full Text] [Related]
9. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck.
Schrijvers AH; Quak JJ; Uyterlinde AM; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Cancer Res; 1993 Sep; 53(18):4383-90. PubMed ID: 8364934
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunoscintigraphy of squamous cell carcinoma in the head and neck region.
Heissler E; Grünert B; Barzen G; Fritsche L; Hell B; Felix R; Bier J
Int J Oral Maxillofac Surg; 1994 Jun; 23(3):149-52. PubMed ID: 7930767
[TBL] [Abstract][Full Text] [Related]
11. Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targetting tumours in the upper aerodigestive and respiratory tract.
De Bree R; Roos JC; Quak JJ; Den Hollander W; Snow GB; Van Dongen GA
Nucl Med Commun; 1994 Aug; 15(8):613-27. PubMed ID: 7970443
[TBL] [Abstract][Full Text] [Related]
12. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
13. The product of the c-erbB-2 proto-oncogene as a target for diagnosis and therapy in breast cancer.
Dean CJ; Allan S; Eccles S; McFarlane C; Styles J; Valeri M; Sandle J; Bakir A; Sacks N
Year Immunol; 1993; 7():182-92. PubMed ID: 8103950
[No Abstract] [Full Text] [Related]
14. Radioimmunoscintigraphy of head and neck cancer using 99mTc-labeled monoclonal antibody E48 F(ab')2.
van Dongen GA; Leverstein H; Roos JC; Quak JJ; van den Brekel MW; van Lingen A; Martens HJ; Castelijns JA; Visser GW; Meijer CJ
Cancer Res; 1992 May; 52(9):2569-74. PubMed ID: 1568225
[TBL] [Abstract][Full Text] [Related]
15. [Immunoscintigraphy of carcinomas in the area of the head-neck with technetium-99m marked monoclonal antibody 174H.64. A new diagnostic procedure].
Kiefer J; Baum RP; Knecht R; Hertel A; Niesen A; von Ilberg C; Hör G
HNO; 1994 Sep; 42(9):546-52. PubMed ID: 7989226
[TBL] [Abstract][Full Text] [Related]
16. Immuno-positron emission tomography: shedding light on clinical antibody therapy.
van Dongen GA; Vosjan MJ
Cancer Biother Radiopharm; 2010 Aug; 25(4):375-85. PubMed ID: 20707716
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunodetection and therapy of breast cancer.
DeNardo SJ
Semin Nucl Med; 2005 Apr; 35(2):143-51. PubMed ID: 15765377
[TBL] [Abstract][Full Text] [Related]
18. Clinical imaging of head and neck cancer with technetium-99m-labeled monoclonal antibody E48 IgG or F(ab')2.
de Bree R; Roos JC; Quak JJ; den Hollander W; van den Brekel MW; van der Wal JE; Tobi H; Snow GB; van Dongen GA
J Nucl Med; 1994 May; 35(5):775-83. PubMed ID: 8176458
[TBL] [Abstract][Full Text] [Related]
19. Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer.
Divgi CR
Oncology (Williston Park); 1996 Jun; 10(6):939-53; discussion 954, 957-8. PubMed ID: 8823804
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship.
Lawrentschuk N; Davis ID; Bolton DM; Scott AM
BJU Int; 2006 May; 97(5):916-22. PubMed ID: 16643471
[No Abstract] [Full Text] [Related]
[Next] [New Search]
